BCR-ABL Mutations in Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors and Impact on Survival

Katia Borgia Barbosa Pagnano, Israel Bendit, Carla Boquimpani, Carmino Antonio De Souza, Eliana C.M. Miranda, Ilana Zalcberg, Irene Larripa, Luciana Nardinelli, Rosana Antunes Silveira, Laura Fogliatto, Nelson Spector, Vaneuza Funke, Ricardo Pasquini, Vania Hungria, Carlos Sérgio Chiattone, Nelma Clementino, Monika Conchon, Elena Beatriz Moiraghi, Jose Luis Lopez, Carolina PavlovskyMiguel A. Pavlovsky, Eduardo E. Cervera, Luis Antonio Meillon, Belinda Simões, Nelson Hamerschlak, Alicia Helena Magarinos Bozzano, Ernesto Mayta, Jorge Cortes, Raquel M. Bengió

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p = 0.01; PFS: 48% vs. 30% p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.

Original languageEnglish (US)
Pages (from-to)451-458
Number of pages8
JournalCancer Investigation
Issue number9
StatePublished - Oct 21 2015
Externally publishedYes


  • BCR-ABL mutations
  • Chronic myeloid leukemia
  • Imatinib
  • Resistance
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'BCR-ABL Mutations in Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors and Impact on Survival'. Together they form a unique fingerprint.

Cite this